Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B).

Authors :: Sim SH
Kim JE
Kim MH
Park YH
Kim JH
Suh KJ
Koh SJ
Park KH
Kang MJ
Ahn MS
Lee KE
Kim HJ
Ahn HK
Kim HJ
Park KU
Byun JH
Park JH
Lee GW
Lee KS
Sohn J
Jung KH
Park IH
Source :: Breast (Edinburgh, Scotland) [Breast] 2022 Oct; Vol. 65, pp. 172-178. Date of Electronic Publication: 2022 Aug 17.
Publication Year :: 2022
Abstract: We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.<br />Competing Interests: Declaration of competing interest The authors declare no competing interests except In Hae Park who was provided Herzuma from Celltrion, Korea for this study.<br /> (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Subjects :: Antineoplastic Combined Chemotherapy Protocols therapeutic use
Dioxolanes
Female
Humans
Receptor, ErbB-2
Trastuzumab
Biosimilar Pharmaceuticals therapeutic use
Breast Neoplasms pathology
Physicians

Full Text Access

Tools